Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Post-Transplant Carfilzomib Plus Lenalidomide/Dexamethasone Provides Superior PFS Benefit Over Lenalidomide in Myeloma

August 26th 2022

Extended treatment with carfilzomib plus lenalidomide and dexamethasone after autologous stem cell transplant improved progression-free survival over standard lenalidomide maintenance in patients with multiple myeloma.

Lenalidomide Combo Plus ASCT Provides Significant PFS Benefit in Multiple Myeloma With High-Risk Cytogenetics

August 26th 2022

The triplet regimen of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation and lenalidomide maintenance therapy significantly improved progression-free survival compared with RVd alone in patients with newly diagnosed multiple myeloma, with notable benefit observed in those with high-risk cytogenetics.

FDA Approves Pemigatinib for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

August 26th 2022

The FDA has approved pemigatinib (Pemazyre) for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms and FGFR1 rearrangement.

Talquetamab Adverse Event Management in Myeloma Requires Early Oral, Dermatologic Interventions

August 25th 2022

Patients with multiple myeloma can mitigate the common oral and dermatologic toxicities associated with talquetamab with early intervention tactics.

Other Novel Therapeutic Agents in Immune Thrombocytopenia

August 25th 2022

Before closing out their discussion on novel treatment approaches in ITP, experts review data behind FcR-, BTK-, and CD38-targeted therapies.

Novel Treatment Strategies in Immune Thrombocytopenia: Complement Inhibitors

August 25th 2022

Panelists review data behind sutimlimab, a complement inhibitor being investigated in the setting of immune thrombocytopenia.

FDA Approves Ibrutinib for Pediatric Patients With Chronic GVHD

August 24th 2022

The FDA has approved ibrutinib (Imbruvica) for pediatric patients aged 1 year or older with chronic graft versus host disease following failure of 1 or more lines of systemic therapy.

Luspatercept-ammt Demonstrates Long-Term Efficacy in LR-MDS

August 24th 2022

Luspatercept, a first-in-class erythroidmaturation agent, induced high clinical activity in patients with transfusion-dependent, lower-risk myelodysplastic syndromes and ring sideroblasts who were relapsed/refractory to erythropoietin, according to findings from the phase 2 PACE-MDS study.

FDA Place Clinical Hold on Phase 1 Trial Examining FHD-286 in Relapsed/Refractory AML and MDS

August 23rd 2022

The FDA has placed a full clinical hold on a phase 1 dose escalation trial investigating the BRG1/BRM inhibitor FHD-286 in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.

EMA Validates Marketing Authorization Application for Quizartinib in Newly Diagnosed FLT3-ITD+ AML

August 23rd 2022

The European Medicines Agency has validated the marketing authorization application for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of adult patients with newly diagnosed FLT3-ITD–mutated acute myeloid leukemia.

Women in Oncology: Resilience That Leads to Innovation

August 23rd 2022

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss how they turned their leukemia career “lemons” into “lemonade.”

EMA Accepts Marketing Authorization Application for Fixed-Dose Decitabine/Cedazuridine Combo in AML

August 22nd 2022

The European Medicines Agency has accepted the marketing authorization application for the oral fixed-dose combination of decitabine and cedazuridine for the frontline treatment of adults with acute myeloid leukemia who are not candidates for standard induction chemotherapy.

Relma-cel Demonstrates Durable Activity in Relapsed/Refractory LBCL

August 22nd 2022

Relmacabtagene autoleucel elicited durable responses and a high overall survival rate in Chinese patients with relapsed/refractory large B-cell lymphoma, according to 2-year follow-up data from the phase 2 RELIANCE trial.

Treatment Advances on the Horizon for Acute GVHD

August 22nd 2022

Shifting their focus to acute graft versus host disease, panelists reflect on evolving treatment strategies and novel therapeutics.

Treatment Advances on the Horizon for Chronic GVHD

August 22nd 2022

Expert panelists share their perspectives on ongoing treatment evolutions in the setting of chronic graft versus host disease.

CAR T-cell Therapy Establishes Prominent Role Across Hematologic Malignancies

August 20th 2022

In recent years, cellular immune therapies such as chimeric antigen receptor T-cell therapy have significantly improved response rates for various hematological malignancies.

Women in Oncology: Bringing Advances From the Lab Into the Clinic

August 19th 2022

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss what motivated them to continue working toward improvements in the leukemia field, even when outcomes were dismal and treatment options were scarce.

Women in Oncology: How Early Treatments Paved the Way for Future Advances

August 18th 2022

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss the challenges that accompanied the lack of progress in leukemia treatment when they began their fellowships and express their excitement about encouraging developments that have since emerged in the arena.

FDA Lifts Partial Clinical Hold on TakeAim Lymphoma Trial Evaluating Emavusertib in B-cell Malignancies

August 18th 2022

The FDA has lifted a partial clinical hold on the open-label, dose-escalating phase 1/2 TakeAim Lymphoma trial investigating the safety and efficacy of emavusertib in patients with relapsed or refractory B-cell malignancies.

Novel Treatment Strategies in Immune Thrombocytopenia: Frontline Use of TPO-RAs

August 18th 2022

Shared insight on clinical trials investigating the frontline use of thrombopoietin receptor agonists in patients with immune thrombocytopenia.